Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan

BACKGROUND: Afatinib is 1 of 3 tyrosine kinase inhibitors approved in the United States for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions (del19) or exon 21 (L858R) substitution muta...

Descripción completa

Detalles Bibliográficos
Autores principales: Graham, Jonathan, Earnshaw, Stephanie, Burslem, Kate, Lim, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397768/
https://www.ncbi.nlm.nih.gov/pubmed/29799327
http://dx.doi.org/10.18553/jmcp.2018.24.6.544

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397768/
https://www.ncbi.nlm.nih.gov/pubmed/29799327
http://dx.doi.org/10.18553/jmcp.2018.24.6.544

Ejemplares similares